News

Senior Biopharma Executive Joins MMS Holdings as Principal Medical Director

Senior Biopharma Executive Joins MMS Holdings as Principal Medical Director

CANTON, Mich. (3/10/2022) – MMS Holdings, a data-focused contract research organization (CRO), announced the addition of Robert Allen, MD, as Principal Medical Director of Global Drug Safety and Pharmacovigilance to its team.

Bringing more than 20 years of pharmaceutical industry experience, Dr. Allen has worked at Parke Davis, Pfizer, Adolor, AstraZeneca, Wyeth, Scirex, Premier, and Inventive/ Syneos. In recent years, he has served as Chief Medical Officer for several start-up companies, including Afferent, Centrexion and Concentric Pharmaceuticals. As CEO of Allen Medical, he has also provided medical and regulatory support for sponsors globally on the design and execution of clinical studies and drug development plans.

Dr. Allen will act as senior technical reviewer for complex projects and provide sponsors with medical advice and regulatory support. Within our medical affairs group, he will be providing expert guidance on safety surveillance, signal detection, risk evaluation, risk mitigation strategies, medical monitoring and more; providing global support for our PV colleagues across MMS.

“MMS is synonymous with quality and is a recognized industry leader in supporting clinical development plans through regulatory submissions,” said Dr. Robert Allen. “I’m excited to bring my many years of diverse drug development, safety, and regulatory experiences to support new and existing MMS clients, with a personal vision and set of goals to provide flawless execution of services, as we strive to bring life-changing therapies to patients around the world.”

“At MMS, our passion is helping clients bring new drugs to the market in a timely manner while upholding the utmost scientific rigor,” said Dr. Uma Sharma, Founder and Chief Scientific Officer of MMS Holdings. “With the addition of Dr. Allen to our Global Drug Safety and Pharmacovigilance team, we will continue to build on our portfolio of clients achieving drug approvals through our regulatory support and expertise. Besides, it will be great to work with Rob again after almost two decades.”

ABOUT MMS  

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for the last three consecutive years.  

Media Contact
Avery Zimmerman

media@mmsholdings.com

Back to MMS News